Search

Your search keyword '"Tisagenlecleucel -- Research -- Product development"' showing total 4 results
Start Over Descriptor "Tisagenlecleucel -- Research -- Product development" Journal hematology week
4 results on '"Tisagenlecleucel -- Research -- Product development"'

1. Studies from University of Southern California (USC) Have Provided New Information about B-Cell Lymphoma (Value of Reducing Wait Times for Chimeric Antigen Receptor T-cell Treatment: Evidence From Randomized Controlled Trial Data On ...)

Subjects
University of Southern California, Care and treatment, Research, Product development, Clinical trials -- Research, Non-Hodgkin lymphomas -- Care and treatment -- Research, Antigens -- Research, T cells -- Research, Tisagenlecleucel -- Research -- Product development, Non-Hodgkin's lymphomas -- Care and treatment -- Research
Abstract

2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Oncology - B-Cell Lymphoma have been published. According to news reporting [...]

Published
2023

2. Investigators at Memorial Sloan-Kettering Cancer Center Describe Findings in B-Cell Lymphoma (Role of Cd19 Chimeric Antigen Receptor T Cells In Second-line Large B Cell Lymphoma: Lessons From Phase 3 Trials. an Expert Panel Opinion From the ...)

Subjects
Memorial Sloan-Kettering Cancer Center, Research, Product development, Clinical trials -- Research, Non-Hodgkin lymphomas -- Research, Antigens -- Research, Axicabtagene ciloleucel -- Research -- Product development, Cancer, T cells -- Research, Tisagenlecleucel -- Research -- Product development, Non-Hodgkin's lymphomas -- Research
Abstract

2022 DEC 19 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Oncology - B-Cell Lymphoma. According to news originating from New [...]

Published
2022

3. Investigators at Massachusetts General Hospital Describe Findings in Lymphoma (Safety and Efficacy of Tisagenlecleucel In Primary Cns Lymphoma: a Phase 1/2 Clinical Trial)

Subjects
Novartis AG -- Product development, United States. National Cancer Institute -- Reports, Massachusetts General Hospital -- Reports, Research, Reports, Product development, Clinical trials -- Research -- Reports, Pharmaceutical industry -- Product development, Drug approval -- Reports -- Research, Lymphomas -- Research, T cells -- Reports -- Research, Tisagenlecleucel -- Research -- Product development
Abstract

2022 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Lymphoma. According to news reporting out of Boston, [...]

Published
2022

4. Researchers from University of Texas MD Anderson Cancer Center Report on Findings in Follicular Lymphoma (Tisagenlecleucel In Adult Relapsed or Refractory Follicular Lymphoma: the Phase 2 Elara Trial)

Subjects
Novartis AG -- Product development, University of Texas. M.D. Anderson Cancer Center, Care and treatment, Research, Product development, Cancer -- Care and treatment, Cancer research, Recurrence (Disease) -- Care and treatment -- Research, Pharmaceutical industry -- Product development, Lymphomas -- Care and treatment -- Research, T cells -- Research, Tisagenlecleucel -- Research -- Product development, Oncology, Experimental, Diseases -- Relapse, Cancer -- Care and treatment -- Research
Abstract

2022 JAN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Oncology - Follicular Lymphoma have been published. According to news reporting [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results